11月3日，Hims & Hers Health Inc.盘中下跌5.22%，报26.235美元/股，成交额1.78亿美元。
消息面上，市场仍在消化公司应对FTC投诉的进展。该投诉指称公司曾误导消费者购买产品，并对不需要的订阅收费；公司此前已请求加州联邦法官驳回相关诉讼，合规与订阅收费问题继续压制短线风险偏好。
同时，公司减重订阅业务此前还被曝出现信用卡纠纷激增，并收到接近7.5万美元相关费用通知，进一步放大市场对用户留存与运营合规的关注。尽管公司近期继续推进澳大利亚业务扩张，但当前交易焦点更集中于监管风险。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.